Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
J Surg Oncol. 2014 Dec;110(8):942-6. doi: 10.1002/jso.23773. Epub 2014 Aug 28.
This multicenter study, which was conducted in northern Kanto, Japan, aimed to assess the efficacy of imatinib mesylate against advanced or recurrent gastrointestinal stromal tumors (GIST).
The clinicopathological data of 234 GIST patients who were treated at one of the 11 participating hospitals from 2001-2011 were retrospectively reviewed. Imatinib was administered as a first-line therapy in cases involving unresectable disease or postoperative recurrence (41 cases). The median follow-up period was 4.0 years.
After a median follow-up period of 4.0 years, the patients treated with imatinib (n = 41) exhibited 1-, 3-, and 5-year overall survival (OS) rates of 92.3%, 74.9%, and 53.8%, respectively. In univariate and multivariate analyses, imatinib dose reduction and achieving a complete or partial response were found to be associated with increased OS.
Long-term imatinib treatment is recommended for patients with non-progressive disease. If patients experience significant toxicities, temporary dose reduction might be useful.
本多中心研究在日本关东北部进行，旨在评估甲磺酸伊马替尼治疗晚期或复发性胃肠道间质瘤（GIST）的疗效。
回顾性分析了 2001 年至 2011 年期间 11 家参与医院的 234 例 GIST 患者的临床病理资料。对于无法切除或术后复发的病例（41 例），给予伊马替尼作为一线治疗。中位随访时间为 4.0 年。
中位随访 4.0 年后，接受伊马替尼治疗的患者（n=41）的 1、3 和 5 年总生存率（OS）分别为 92.3%、74.9%和 53.8%。单因素和多因素分析显示，伊马替尼剂量减少和达到完全或部分缓解与 OS 延长相关。
对于无进展性疾病的患者，建议长期使用伊马替尼治疗。如果患者出现严重毒性反应，暂时减少剂量可能是有用的。
Zotero 插件